Archive: Legal, Ethical and Policy Considerations in Adopting Pathogen Reduction Technology

258 views · Published 20 October 2015 · 57:59 · Indexed 12 November 2026

Channel: UW Video · 2015 · Education

Watch on YouTube

Upon arrival of 2015, FDA surprised the transfusion medicine community by announcing its licensure of pathogen-reduced apheresis platelets and plasma. Pathogen reduction technology has been a "holy grail" of transfusion medicine because it can inactivate a broad spectrum of infectious agents, known and unknown. The technology is expensive, however, and the risk profile, while encouraging so far, is not fully defined. This talk will present a framework for risk-based decision making on the adoption of pathogen reduction, with an emphasis on legal and ethical considerations that impact policy formulation.

James Barbeau, MD, JD, director, Clinical Pathology, Brown University

09/30/2015

https://uw.edu/video
The University of Washington is committed to ensuring digital accessibility in our services, programs, and activities. If you encounter accessibility barriers using videos found on this channel, please contact UW Video at uwvideo [at] uw [dot] edu.

More from this channel